NSIS-B Stock Analysis: Novonesis (Novozymes) | CO
Specialty Chemicals | CO, Denmark | Market Cap: 197.634m DKK | 12M Return: -6.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 210M
EPS Trend: -28.0%
Qual. Beats: 0
Rev. Trend: -76.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Novonesis (Novozymes) A/S (NSIS-B) is a Denmark-based specialty chemicals company that develops, produces, and sells industrial enzymes, functional proteins, and microbial products across a global footprint spanning Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America. Its biosolutions serve a diverse set of end-markets, including food and beverage (dairy, baking, beverages, plant-based proteins), bioenergy (biodiesel, biogas, ethanol), household and industrial cleaning, human health (gut, immune, and oral health), agriculture (crop and animal nutrition), textiles, and pulp and paper. The companys core product portfolio centers on enzyme classes such as lipases, proteases, oxidoreductases, and carbohydrases, which are used as biological catalysts in industrial processes to replace or reduce conventional chemical inputs, lower energy consumption, and improve process efficiency. Novonesis is headquartered in Lyngby, Denmark, and is classified within the GICS Materials sector under Specialty Chemicals.
- Food and beverage biosolutions revenue accelerates post Chr. Hansen merger
- Bioenergy enzyme demand grows on renewable diesel and ethanol mandates
- Household care enzyme sales expand with premium washing product adoption
| Net Income: 596.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -14.24 > 1.0 |
| NWC/Revenue: 19.60% < 20% (prev 4.47%; Δ 15.13% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.28b > Net Income 596.9m |
| Net Debt (3.25b) to EBITDA (1.68b): 1.93 < 3 |
| Current Ratio: 1.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.2m) vs 12m ago -0.40% < -2% |
| Gross Margin: 54.33% > 18% (prev 52.20%; Δ 2.13% > 0.5%) |
| Asset Turnover: 26.60% > 50% (prev 115.4%; Δ -88.77% > 0%) |
| Interest Coverage Ratio: -2.20 > 6 (EBIT TTM -153.4m / Interest Expense TTM 69.9m) |
| A: 0.05 (Total Current Assets 2.05b - Total Current Liabilities 1.22b) / Total Assets 16.5b |
| B: 0.67 (Retained Earnings 11.1b / Total Assets 16.5b) |
| C: -0.01 (EBIT TTM -153.4m / Avg Total Assets 15.8b) |
| D: 1.95 (Book Value of Equity 10.9b / Total Liabilities 5.60b) |
| Altman-Z'' = 4.50 = AA |
| DSRI: 3.0 (Receivables 923.6m/877.7m, Revenue 4.20b/17.4b) |
| GMI: 0.96 (GM 52.20% / 54.33%) |
| AQI: 1.02 (AQ_t 0.69 / AQ_t-1 0.68) |
| SGI: 0.24 (Revenue 4.20b / 17.4b) |
| TATA: -0.04 (NI 596.9m - CFO 1.28b) / TA 16.5b) |
| Beneish M = -1.95 (Cap -4..+1) = B |
As of July 29, 2026, the stock is trading at DKK 403.80 with a total of 515,686 shares traded. Over the past week, the price has changed by -4.67%, over one month by -0.93%, over three months by +6.10% and over the past year by -6.64%.
Current recommended Stop Loss: 386.50 (which is 4.3% or 1.8 ATR below the current price).
Novonesis (Novozymes) has no consensus analysts rating.
Market Cap EUR = 26.4b (198b DKK * 0.1337 DKK.EUR)
P/E Trailing = 44.2947
P/E Forward = 27.7778
P/S = 47.0636
P/B = 2.4137
P/EG = 2.2047
Revenue TTM = 4.20b EUR
EBIT TTM = -153.4m EUR
EBITDA TTM = 1.68b EUR
Long Term Debt = 2.92b EUR (from longTermDebt, last quarter)
Short Term Debt = 289.1m EUR (from shortTermDebt, last quarter)
Debt = 3.58b EUR (from shortLongTermDebtTotal, last quarter) + Leases 369.0m
Net Debt = 3.25b EUR (calculated: Debt 3.58b - CCE 329.4m)
Enterprise Value = 29.7b EUR (26.4b + Debt 3.58b - CCE 329.4m)
Interest Coverage Ratio = -2.20 (Ebit TTM -153.4m / Interest Expense TTM 69.9m)
EV/FCF = 37.16x (Enterprise Value 29.7b / FCF TTM 798.7m)
FCF Yield = 2.69% (FCF TTM 798.7m / Enterprise Value 29.7b)
FCF Margin = 19.01% (FCF TTM 798.7m / Revenue TTM 4.20b)
Net Margin = 14.21% (Net Income TTM 596.9m / Revenue TTM 4.20b)
Gross Margin = 54.33% ((Revenue TTM 4.20b - Cost of Revenue TTM 1.92b) / Revenue TTM)
Gross Margin QoQ = 56.66% (prev 56.07%)
Tobins Q-Ratio = 1.80 (Enterprise Value 29.7b / Total Assets 16.5b)
Interest Expense / Debt = 1.95% (Interest Expense 69.9m / Debt 3.58b)
Taxrate = 21.03% (159.0m / 755.9m)
NOPAT = -121.1m (EBIT -153.4m * (1 - 21.03%)) [loss with tax shield]
Current Ratio = 1.67 (Total Current Assets 2.05b / Total Current Liabilities 1.22b)
Debt / Equity = 0.33 (Debt 3.58b / totalStockholderEquity, last quarter 10.9b)
Debt / EBITDA = 1.93 (Net Debt 3.25b / EBITDA 1.68b)
Debt / FCF = 4.07 (Net Debt 3.25b / FCF TTM 798.7m)
Total Stockholder Equity = 10.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.78% (Net Income 596.9m / Total Assets 16.5b)
RoE = 5.52% (Net Income TTM 596.9m / Total Stockholder Equity 10.8b)
RoCE = -1.12% (EBIT -153.4m / Capital Employed (Equity 10.8b + L.T.Debt 2.92b))
RoIC = -0.79% (negative operating profit) (NOPAT -121.1m / Invested Capital 15.4b)
WACC = 5.59% (E(26.4b)/V(30.0b) * Re(6.14%) + D(3.58b)/V(30.0b) * Rd(1.95%) * (1-Tc(0.21)))
Discount Rate = 6.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.32 | Cagr: 25.75%
[DCF] Terminal Value 73.10% ; FCFF base≈1.63b ; Y1≈1.43b ; Y5≈1.15b
[DCF] Fair Price = 37.01 (EV 18.5b - Net Debt 3.25b = Equity 15.3b / Shares 412.5m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -28.03 | EPS CAGR: -5.94% | SUE: 0.06 | # QB: 0
Revenue Correlation: -76.35 | Revenue CAGR: -43.89% | SUE: -0.65 | # QB: 0
EPS current Quarter (2026-06-30): EPS=7.47 | Chg30d=+31.27% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=7.25 | Chg30d=+26.62% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=16.05 | Chg30d=+0.70% | Revisions=+50% | GrowthEPS=+7.9% | GrowthRev=+6.9%
EPS next Year (2027-12-31): EPS=17.66 | Chg30d=+1.11% | Revisions=+50% | GrowthEPS=+10.1% | GrowthRev=+7.4%
[Analyst] Revisions Ratio: +36% (up=6, down=2)